Alzheimer's Disease Assay
Alzheimer's Disease
PreclinicalActive
Key Facts
About TissueVision
TissueVision is a private, revenue-generating contract research organization (CRO) focused on high-resolution 3D whole-tissue imaging and analysis. The company's core technology is its TissueCyte® imaging platform, which automates tissue sectioning and multi-spectral imaging to generate terabytes of quantitative data per study, enabling large-scale projects in neuroscience, oncology, and fibrosis. With a strong foundation from MIT and NIH grant support, TissueVision serves as a critical partner for clients needing scalable, statistically powerful histological data to advance therapeutic programs from discovery through preclinical development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |